ARL4D

Across TCGA pan-cancer cohorts, ARL4D Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARL4D data layer compared with 27 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ARL4D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARL4D expression acts as an unfavorable survival marker.

SCLC, ACC, and ESCA are the cancer types where ARL4D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARL4D–SCLC (OS)

Open the SCLC breakdown →